Impacts of rifaximin and midodrine on morbidity, mortality, and quality of life in patients with decompensated liver cirrhosis.
Maha Mohammad ElsabaawyMedhat AssemHanaa BadranAsmaa MahmoudDalia ElsabaawyAmr Ragab
Published in: European journal of gastroenterology & hepatology (2024)
Combined midodrine with rifaximin represents an endowment to patients with DLC with spectacular improvements in synthetic liver functions, along with improved quality of life, and survival.